ANTIBODY TO LILRB2

To provide an anti-LILRB2 antibody that can be used in a method for treating a disease such as cancer.SOLUTION: An antibody specifically binds to human LILRB2, where the antibody includes six complementarity determining regions (CDR) of (a) CDR-H1, (b) CDR-H2, (c) CDR-H3, (d) CDR-L1, (e) CDR-L2, and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	YASMIN RAMSAY, HEATHER B COHEN, DONALD RAYMOND SHAFFER, LAUREN PEPPER MACKENZIE, KEVIN PATRICK GUAY, KRISTIN SHANEA O'MALLEY, JEFFREY YAN-FEI SMITH
Format:	Patent
Sprache:	eng ; jpn
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To provide an anti-LILRB2 antibody that can be used in a method for treating a disease such as cancer.SOLUTION: An antibody specifically binds to human LILRB2, where the antibody includes six complementarity determining regions (CDR) of (a) CDR-H1, (b) CDR-H2, (c) CDR-H3, (d) CDR-L1, (e) CDR-L2, and (f) CDR-L3 each of which includes a specific amino acid sequence having a different sequence. The antibody may block binding of human LILRB2 with HLA-G and/or HLA-A2.SELECTED DRAWING: Figure 1 【課題】がんなどの疾患を治療する方法で使用できる、抗ＬＩＬＲＢ２抗体を提供する。【解決手段】ヒトＬＩＬＲＢ２と特異的に結合する抗体であって、前記抗体が、それぞれ配列が異なる、ある特定のアミノ酸配列を含む、（ａ）ＣＤＲ－Ｈ１、（ｂ）ＣＤＲ－Ｈ２、（ｃ）ＣＤＲ－Ｈ３、（ｄ）ＣＤＲ－Ｌ１、（ｅ）ＣＤＲ－Ｌ２、及び（ｆ）ＣＤＲ－Ｌ３の６つの相補性決定領域（ＣＤＲ）を含む、前記抗体。該抗体は、ＨＬＡ－Ｇ及び／またはＨＬＡ－Ａ２のヒトＬＩＬＲＢ２との結合を遮断してよい。【選択図】図１